CA2602324C - Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer - Google Patents

Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer Download PDF

Info

Publication number
CA2602324C
CA2602324C CA2602324A CA2602324A CA2602324C CA 2602324 C CA2602324 C CA 2602324C CA 2602324 A CA2602324 A CA 2602324A CA 2602324 A CA2602324 A CA 2602324A CA 2602324 C CA2602324 C CA 2602324C
Authority
CA
Canada
Prior art keywords
compound according
independently selected
compound
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2602324A
Other languages
English (en)
French (fr)
Other versions
CA2602324A1 (en
Inventor
Christopher McGuigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana PLC filed Critical Nucana PLC
Publication of CA2602324A1 publication Critical patent/CA2602324A1/en
Application granted granted Critical
Publication of CA2602324C publication Critical patent/CA2602324C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2602324A 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer Expired - Lifetime CA2602324C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505781.5 2005-03-21
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2602324A1 CA2602324A1 (en) 2006-09-28
CA2602324C true CA2602324C (en) 2015-02-24

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602324A Expired - Lifetime CA2602324C (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Country Status (20)

Country Link
US (1) US8263575B2 (https=)
EP (1) EP1866324B1 (https=)
JP (2) JP5345381B2 (https=)
CN (2) CN101175763A (https=)
AT (1) ATE471334T1 (https=)
AU (1) AU2006226182C1 (https=)
BR (1) BRPI0609704B8 (https=)
CA (1) CA2602324C (https=)
CY (1) CY1111538T1 (https=)
DE (1) DE602006014949D1 (https=)
DK (1) DK1866324T3 (https=)
ES (1) ES2348741T3 (https=)
GB (1) GB0505781D0 (https=)
IL (1) IL186104A (https=)
MX (1) MX2007011666A (https=)
PL (1) PL1866324T3 (https=)
PT (1) PT1866324E (https=)
SI (1) SI1866324T1 (https=)
WO (1) WO2006100439A1 (https=)
ZA (1) ZA200709011B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (en) * 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
MX2016015568A (es) * 2014-05-28 2017-07-04 Idenix Pharmaceuticals Llc Derivados de nucleosidos para el tratamiento del cancer.
LT3224268T (lt) * 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CA3005444A1 (en) 2015-11-16 2017-05-26 Ichorion Therapeutics, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) * 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP0821692B1 (en) 1995-04-21 2006-01-11 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
IL137164A0 (en) * 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides

Also Published As

Publication number Publication date
JP2013173786A (ja) 2013-09-05
JP5863702B2 (ja) 2016-02-17
SI1866324T1 (sl) 2010-10-29
IL186104A (en) 2013-06-27
EP1866324A1 (en) 2007-12-19
CY1111538T1 (el) 2015-08-05
DE602006014949D1 (de) 2010-07-29
MX2007011666A (es) 2007-11-14
PT1866324E (pt) 2010-09-16
US8263575B2 (en) 2012-09-11
ATE471334T1 (de) 2010-07-15
CN103936807A (zh) 2014-07-23
AU2006226182A1 (en) 2006-09-28
US20090215715A1 (en) 2009-08-27
CA2602324A1 (en) 2006-09-28
CN101175763A (zh) 2008-05-07
AU2006226182C1 (en) 2012-06-14
IL186104A0 (en) 2008-01-20
PL1866324T3 (pl) 2010-12-31
BRPI0609704A2 (pt) 2010-04-20
JP5345381B2 (ja) 2013-11-20
WO2006100439A1 (en) 2006-09-28
JP2008533191A (ja) 2008-08-21
ZA200709011B (en) 2009-01-28
BRPI0609704B1 (pt) 2020-12-01
DK1866324T3 (da) 2010-09-27
ES2348741T3 (es) 2010-12-13
GB0505781D0 (en) 2005-04-27
BRPI0609704B8 (pt) 2021-09-28
AU2006226182B2 (en) 2011-09-01
EP1866324B1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CA2602324C (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
US20220033433A1 (en) Process for preparing nucleoside prodrugs
RU2464272C2 (ru) Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с
EP2625187B1 (en) Phosphoramidite derivatives of gemcitabine for use in the treatment cancer
HK1230204A1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1230204B (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1210784B (en) Process for preparing nucleoside prodrugs
HK1161265A (en) Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250922

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106